Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q3 FY2025 Earnings Presentation
24 slides from Valiant Organics's earnings presentation, Feb 18, 2025
Slide 1: Cover letter to stock exchanges: Investors' Presentation
February 18, 2025 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1, Dalal Street G Block Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai- 400 051. SCRIP CODE - 540145 S
Slide 2: Earnings Presentation Q3/9M-FY25
Ea r ni n gs P re s e nta ti o n | Q 3 /9 M - F Y 2 5
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 5: Chemistries And Product Basket
Chemistries And Product Basket 9M-FY25 Revenue Share Hydrogenation Ammonolysis 44% Key Products: Industries Served: Key Products: • Ortho Anisidine Industries Served: • Dyes • Para Nitro Aniline • Para Anisidine • Dyes • Pigments • Ortho Chloro Para Nitro Aniline • IPPCA • Pigments • Pharmaceutical
Slide 6: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 27,000 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 7: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 8: Q3/9M-FY25 Highlights
Q3/9M-FY25 HIGHLIGHTS Valiant Organics Limited | Q3-2025 7
Slide 9: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS Q3-FY25 CONSOLIDATED FINANCIAL HIGHLIGHTS 9M-FY25 CONSOLIDATED FINANCIAL HIGHLIGHTS INR 1,869 Mn INR 5,149 Mn Operational Revenue Operational Revenue INR 154 Mn INR 334 Mn Operating EBITDA Operating EBITDA 8.24% 6.49% Operating EBITDA Margin Operating EBITDA Margin
Slide 10: Q3/9M-FY25 Operational Highlights
Q3/9M-FY25 Operational Highlights Q3-FY25 Revenue Break-up – Chemistries • Strong demand revival witnessed across all 3 key chemistries, ensuring good revenue Others, 5% EBITDA growth, although pricing pressures remain a challenge. Chlorination, • Strong production volume with improved utilizations,
Slide 11: Key Chemistries
Key Chemistries Chlorination (INR Mn) Hydrogenation (INR Mn) Ammonolysis (INR Mn) Others (INR Mn) 10 00 879 380 60 0 14 0 366 90 0 513 118 40 0 730 479 105 REVENUES 12 0 80 0 97 50 0 35 0 274 70 0 605 404 10 0 30 0 40 0 60 0 25 0 80 50 0 30 0 20 0 60 40 0 15 0 20 0 30 0 40 10 0 20 0 10 0 20 50 10 0
Slide 12: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance Particulars (INR Mn) Q3-FY25 Q3-FY24 Y-o-Y Q2-FY25 Q-o-Q Revenue from Operations 1,869 1,414 32.2% 1,602 16.7% Total Expenses 1,715 1,376 24.6% 1,578 8.7% EBITDA 154 38 NA 24 NA EBITDA Margins (%) 8.24% 2.69% 555 Bps 1.5% 674 Bps Other Income 50 4 NA 25 N
Slide 13: YTD Consolidated Financial Performance
YTD Consolidated Financial Performance Particulars (INR Mn) 9M-FY25 9M-FY24 Y-o-Y Revenue from Operations 5,149 5,463 (5.7)% Total Expenses 4,815 5,031 (4.3)% EBITDA 334 432 (22.7)% EBITDA Margins (%) 6.49% 7.91% (142) Bps Other Income 80 72 11.1% Depreciation 266 262 1.5% Finance Cost 190 123 54.5%
Slide 14: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance Particulars (INR Mn) Q3-FY25 Q3-FY24 Y-o-Y Q2-FY25 Q-o-Q Revenue from Operations 1,869 1,414 32.2% 1,602 16.7% Total Expenses 1,715 1,376 24.6% 1,579 8.6% EBITDA 154 38 NA 23 NA EBITDA Margins (%) 8.24% 2.69% 555 Bps 1.44% 680 Bps Other Income 50 4 NA 20 NA
Slide 15: YTD Standalone Financial Performance
YTD Standalone Financial Performance Particulars (INR Mn) 9M-FY25 9M-FY24 Y-o-Y Revenue from Operations 5,149 5,004 2.9% Total Expenses 4,814 4,591 4.9% EBITDA 335 413 (18.9)% EBITDA Margins (%) 6.51% 8.25% (174) Bps Other Income 74 9 NA Depreciation 266 252 5.6% Finance Cost 190 123 54.5% Profit Be
Slide 16: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW Valiant Organics Limited | Q3-2025 15
Slide 17: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY22 FY23 FY24 9M-FY25 Revenue from Operations 11,533 10,518 7,231 5,149 Total Expenses 9,484 8,875 6,849 4,815 EBITDA 2,049 1,643 382 334 EBITDA Margins (%) 17.77% 15.62% 5.28% 6.49% Other Income 74 80 93 80 Depreciation 296 292 349 266
Slide 18: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Particulars (INR Mn) FY23 FY24 H1-FY25 Particulars (INR Mn) FY23 FY24 H1-FY25 EQUITY 7,401 7,293 7,166 Non-Current Assets 7,682 8,352 8,305 a) Equity Share Capital 272 276 276 a) Property, Plant and Equipment 6,565 6,297 6,239 b) Other Equity 6,616 7,017 6,887 c
Slide 19: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY22 FY23 FY24 9M-FY25 Revenue from Operations 9,484 9,116 6,772 5,149 Total Expenses 7,811 7,817 6,376 4,814 EBITDA 1,673 1,299 396 335 EBITDA Margins (%) 17.64% 14.25% 5.85% 6.51% Other Income 33 29 29 74 Depreciation 273 276 340 266 Fina
Slide 20: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY23 FY24 H1-FY25 Particulars (INR Mn) FY23 FY24 H1-FY25 EQUITY 6,661 6,649 6,537 Non-Current Assets 7,424 7,818 7,790 a) Equity Share Capital 272 276 276 a) Property, Plant and Equipment 6,092 6,297 6,239 b) Other Equity 6,385 6,373 6,261 b) Right-Of-Us
Slide 21: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 11,533 1,400 1,279 10,518 2,049 10,00 0 1,643 1,100 1,026 7,500 7,231 800 5,149 5,000 500 17.77% 15.62% 382 334 11.09% 9.75% 2,500 -76 200 5.28% 6.49% -84 - -10 0 FY22 F
Slide 22: Capital Market Information
Capital Market Information Share Price up to 31st December, 2024 30% 10% -10% -30% -50% -70% Jan-24 Feb-24 Mar-24 Apr-24 May-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Valiant Organics Sensex Shareholding pattern (As on 31st December, 2024) Price Data (As on 31st December, 2024) INR FII; 0.
Slide 23: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy , completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all even
Slide 24: Thank You
THANK YOU Valiant Organics Limited | Q3-2025 23